Literature DB >> 21074045

A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells.

Maria C N Marchetto1, Cassiano Carromeu, Allan Acab, Diana Yu, Gene W Yeo, Yangling Mu, Gong Chen, Fred H Gage, Alysson R Muotri.   

Abstract

Autism spectrum disorders (ASD) are complex neurodevelopmental diseases in which different combinations of genetic mutations may contribute to the phenotype. Using Rett syndrome (RTT) as an ASD genetic model, we developed a culture system using induced pluripotent stem cells (iPSCs) from RTT patients' fibroblasts. RTT patients' iPSCs are able to undergo X-inactivation and generate functional neurons. Neurons derived from RTT-iPSCs had fewer synapses, reduced spine density, smaller soma size, altered calcium signaling and electrophysiological defects when compared to controls. Our data uncovered early alterations in developing human RTT neurons. Finally, we used RTT neurons to test the effects of drugs in rescuing synaptic defects. Our data provide evidence of an unexplored developmental window, before disease onset, in RTT syndrome where potential therapies could be successfully employed. Our model recapitulates early stages of a human neurodevelopmental disease and represents a promising cellular tool for drug screening, diagnosis and personalized treatment.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21074045      PMCID: PMC3003590          DOI: 10.1016/j.cell.2010.10.016

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  59 in total

Review 1.  The phenotypic consequences of MECP2 mutations extend beyond Rett syndrome.

Authors:  Sara Hammer; Naghmeh Dorrani; Joanna Dragich; Shinichi Kudo; Carolyn Schanen
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2002

2.  Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations.

Authors:  Christopher A Chapleau; Gaston D Calfa; Meredith C Lane; Asher J Albertson; Jennifer L Larimore; Shinichi Kudo; Dawna L Armstrong; Alan K Percy; Lucas Pozzo-Miller
Journal:  Neurobiol Dis       Date:  2009-05-12       Impact factor: 5.996

3.  Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution.

Authors:  Nimet Maherali; Rupa Sridharan; Wei Xie; Jochen Utikal; Sarah Eminli; Katrin Arnold; Matthias Stadtfeld; Robin Yachechko; Jason Tchieu; Rudolf Jaenisch; Kathrin Plath; Konrad Hochedlinger
Journal:  Cell Stem Cell       Date:  2007-06-07       Impact factor: 24.633

4.  Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons.

Authors:  S Takamori; J S Rhee; C Rosenmund; R Jahn
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

5.  Mild overexpression of MeCP2 causes a progressive neurological disorder in mice.

Authors:  Ann L Collins; Jonathan M Levenson; Alexander P Vilaythong; Ronald Richman; Dawna L Armstrong; Jeffrey L Noebels; J David Sweatt; Huda Y Zoghbi
Journal:  Hum Mol Genet       Date:  2004-09-06       Impact factor: 6.150

6.  Prevalence of autism spectrum disorders--autism and developmental disabilities monitoring network, six sites, United States, 2000.

Authors: 
Journal:  MMWR Surveill Summ       Date:  2007-02-09

7.  An altered neonatal behavioral phenotype in Mecp2 mutant mice.

Authors:  Jonathan D Picker; Rebecca Yang; Laura Ricceri; Joanne Berger-Sweeney
Journal:  Neuroreport       Date:  2006-04-03       Impact factor: 1.837

8.  Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice.

Authors:  Daniela Tropea; Emanuela Giacometti; Nathan R Wilson; Caroline Beard; Cortina McCurry; Dong Dong Fu; Ruth Flannery; Rudolf Jaenisch; Mriganka Sur
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-10       Impact factor: 11.205

9.  Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.

Authors:  Igor Nudelman; Annie Rebibo-Sabbah; Marina Cherniavsky; Valery Belakhov; Mariana Hainrichson; Fuquan Chen; Jochen Schacht; Daniel S Pilch; Tamar Ben-Yosef; Timor Baasov
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

10.  Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs.

Authors:  Gabsang Lee; Eirini P Papapetrou; Hyesoo Kim; Stuart M Chambers; Mark J Tomishima; Christopher A Fasano; Yosif M Ganat; Jayanthi Menon; Fumiko Shimizu; Agnes Viale; Viviane Tabar; Michel Sadelain; Lorenz Studer
Journal:  Nature       Date:  2009-08-19       Impact factor: 49.962

View more
  611 in total

1.  Three-Dimensional Hyaluronic Acid Hydrogel-Based Models for In Vitro Human iPSC-Derived NPC Culture and Differentiation.

Authors:  Shaohua Wu; Ranjie Xu; Bin Duan; Peng Jiang
Journal:  J Mater Chem B       Date:  2017-04-19       Impact factor: 6.331

2.  Evidence for premature aging due to oxidative stress in iPSCs from Cockayne syndrome.

Authors:  Luciana Nogueira de Sousa Andrade; Jason L Nathanson; Gene W Yeo; Carlos Frederico Martins Menck; Alysson Renato Muotri
Journal:  Hum Mol Genet       Date:  2012-06-01       Impact factor: 6.150

3.  Defining the optimal window for cranial transplantation of human induced pluripotent stem cell-derived cells to ameliorate radiation-induced cognitive impairment.

Authors:  Munjal M Acharya; Vahan Martirosian; Lori-Ann Christie; Lara Riparip; Jan Strnadel; Vipan K Parihar; Charles L Limoli
Journal:  Stem Cells Transl Med       Date:  2014-11-12       Impact factor: 6.940

Review 4.  Complexities of Rett syndrome and MeCP2.

Authors:  Rodney C Samaco; Jeffrey L Neul
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

5.  Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin.

Authors:  Bethany L Johnson-Kerner; Faizzan S Ahmad; Alejandro Garcia Diaz; John Palmer Greene; Steven J Gray; Richard Jude Samulski; Wendy K Chung; Rudy Van Coster; Paul Maertens; Scott A Noggle; Christopher E Henderson; Hynek Wichterle
Journal:  Hum Mol Genet       Date:  2014-11-04       Impact factor: 6.150

Review 6.  Diseases in a dish: modeling human genetic disorders using induced pluripotent cells.

Authors:  Gustavo Tiscornia; Erica Lorenzo Vivas; Juan Carlos Izpisúa Belmonte
Journal:  Nat Med       Date:  2011-12       Impact factor: 53.440

Review 7.  Cellular reprogramming: recent advances in modeling neurological diseases.

Authors:  Guo-Li Ming; Oliver Brüstle; Alysson Muotri; Lorenz Studer; Marius Wernig; Kimberly M Christian
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

Review 8.  Stem cells and modeling of autism spectrum disorders.

Authors:  Beatriz C G Freitas; Cleber A Trujillo; Cassiano Carromeu; Marianna Yusupova; Roberto H Herai; Alysson R Muotri
Journal:  Exp Neurol       Date:  2012-10-02       Impact factor: 5.330

Review 9.  Induced pluripotent stem cells: the new patient?

Authors:  Milena Bellin; Maria C Marchetto; Fred H Gage; Christine L Mummery
Journal:  Nat Rev Mol Cell Biol       Date:  2012-10-04       Impact factor: 94.444

10.  Efficient Generation of CA3 Neurons from Human Pluripotent Stem Cells Enables Modeling of Hippocampal Connectivity In Vitro.

Authors:  Anindita Sarkar; Arianna Mei; Apua C M Paquola; Shani Stern; Cedric Bardy; Jason R Klug; Stacy Kim; Neda Neshat; Hyung Joon Kim; Manching Ku; Maxim N Shokhirev; David H Adamowicz; Maria C Marchetto; Roberto Jappelli; Jennifer A Erwin; Krishnan Padmanabhan; Matthew Shtrahman; Xin Jin; Fred H Gage
Journal:  Cell Stem Cell       Date:  2018-05-03       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.